Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous

NCT02681172 is registered in ClinicalTrials.gov with Lantheus Biosciences Ltd. as lead sponsor.

NCT NCT02681172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02681172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous
Lead sponsor
Lantheus Biosciences Ltd.
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2015
Completion date
November 30, 2016
Enrollment
218 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)